Modulating the AIBP-CAV1-VEGFR3 axis to treat lymphatic disorders
This invention is a method of promoting lymphangiogenesis in order to treat lymphatic disorders, namely lymphedema and Alzheimer’s disease (AD). VEGFC-induced VEGFR3 signaling is the major driver of lymphangiogenesis, however the distinct molecular mechanisms determining how VEGFR3 signaling controls lymphatic endothelial cell (LEC) fate remains...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Jun-dae Kim
Keywords(s):
Category(s): Clinical Area > Metabolic Disease, Inflammation, and Immunology, Clinical Area > Neurology, Clinical Area > Cardiovascular, Research Area > Heart and Vascular, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Biologics
|
Beclin 2-Functionalized Therapies for Treatment of Neurodegenerative Disease and Cancer
This invention identified that Beclin 2 functions as a negative regulator of the ERK1/2 signaling, NF-κB signaling, and inflammasome activation. Furthermore, these studies demonstrated that Beclin 2 targets key signalling kinases for degradation through an ATG9A-dependent autophagic pathway. These new findings have uncovered an important role...
Published: 9/13/2024
|
Inventor(s): Rongfu Wang, Helen (Yicheng) Wang, Motao Zhu
Keywords(s):
Category(s): Clinical Area > Cancer, Clinical Area > Neurology, Research Area > Cancer, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Biologics, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Immunotherapy
|
A DNAzyme that targets the CAG repeat RNA in polyglutamine diseases
The invention is a synthetic single-stranded DNA molecule that functions as a specific RNA-cleaving DNA enzyme (or DNAzyme) as a potential therapeutic for the treatment of polyglutamine diseases. The binding arms of this synthetic DNAzyme are complementary to the CAG repeats found in the pathological expansion of CAG trinucleotide repeats in the translated...
Published: 12/24/2024
|
Inventor(s): Nan Zhang, Tetsuo Ashizawa
Keywords(s):
Category(s): Clinical Area > Neurology, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies
|
Neural/Glial Cell-Derived Nanoparticles to Restore Neural Function in Alzheimer’s Disease
This invention is an engineered biomimetic nanoparticle (NP) that integrates neural or glial cell membrane proteins into lipid-based nanoparticles (a.k.a. neurosomes). The integration of these neural/glial cell proteins within the NP shell enable precise targeting to treat a variety of neurological disorders resulting from trauma, neurodegeneration,...
Published: 10/8/2024
|
Inventor(s): Robert Krencik, Assaf Zinger, Ennio Tasciotti, Caroline Cvetkovic
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Drug Delivery, Technology Classifications > Therapeutic > Nanovesicles, Clinical Area > Neurology, Research Area > Neurology and Neurosurgery, Research Area > Nanomedicine
|